Oncternal falls after deprioritizing development of bone cancer therapy

Oncternal Therapeutics

13/04/2022 16:13

** Shares of drug developer  ONCT.O  down 3% at $1.13
    ** ONCT says it has deprioritized further development of its
drug candidate, ONCT-216, and discontinued enrollment in its
early-to-mid stage study in patients with Ewing sarcoma, a rare
bone cancer  urn:newsml:reuters.com:*:nGNX3fwnTw
    ** Says resources will be primarily reallocated to a
late-stage study of its most advanced drug candidate,
zilovertamab
    ** Study to begin in Q3 and will test the drug in patients
who have relapsed or are resistant to treatment for mantle cell
lymphoma, a cancer affecting a part of the immune system - co
    ** Stock has halved in value YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))